Pedro Garbes Selected Research

tixagevimab

10/2022	Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
1/2022	Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pedro Garbes Research Topics

Disease

3	Dengue (Dengue Fever) 01/2020 - 12/2013
2	COVID-19 10/2022 - 01/2022
1	Fever (Fevers) 10/2022
1	Disease Progression 10/2022
1	Severe Dengue 01/2020
1	Infections 07/2015
1	Communicable Diseases (Infectious Diseases) 06/2013

Drug/Important Bio-Agent (IBA)

3	VaccinesIBA 01/2020 - 06/2013
2	cilgavimabIBA 10/2022 - 01/2022
2	tixagevimabIBA 10/2022 - 01/2022
2	AntigensIBA 10/2022 - 07/2015
1	Pharmaceutical PreparationsIBA 10/2022
1	Monoclonal AntibodiesIBA 10/2022
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2022
1	cilgavimab and tixagevimab drug combinationIBA 01/2022
1	Dengue VaccinesIBA 07/2015
1	Neutralizing AntibodiesIBA 12/2013